By Trusted AI News
Healthcare is moving toward a more continuous model of care. The startups drawing attention are helping providers build healthier populations between visits, improve earlier detection, and advance new therapies for diseases that have long lacked good options.
This is a look at ten companies with a clear healthcare story in 2026: a stronger care model, a meaningful clinical step, a practical expansion, or a technology that could change how providers and researchers work.
1. Actuvi
Actuvi builds digital-care and remote-monitoring programs for providers, clinics, and hospitals. Patients remain within the provider’s own ecosystem, rather than going to random providers. Whatever a care organization needs for remote care, Actuvi builds it for the health orgs using their existing care pathways.
Actuvi’s platform gives the care team a more complete picture of the patient, rather than a single snapshot from the last in-clinic visit. It is designed to supplement in-clinic care. Providers can configure digital intake, multilingual consent, patient requests, scheduled assessments, messaging, care plans, and PROMs/PREMs around their own specialty and workflows. They can use assessments such as PHQ-9 and GAD-7 when appropriate, and clinical-threshold sorting helps teams focus their work queue while providers remain responsible for review and clinical decisions.
Actuvi is growing rapidly in the United States and expanding into other countries. It is worth watching because it helps healthcare organizations create a longitudinal health baseline and deliver digital care without giving up on their workflows.
2. Neko Health
Neko Health is making preventative care feel more concrete. Its in-person health assessments combine proprietary technology, software, and clinician interpretation to help people understand key health signals before they become a crisis.
The company is preparing for its first U.S. locations, beginning in New York, after establishing a clear public profile in Europe. That expansion makes Neko Health a company to watch because it is testing whether a more proactive, accessible assessment model can become part of everyday healthcare rather than a niche service.
3. Isomorphic Labs
Isomorphic Labs develops systems intended to help researchers design drug candidates across therapeutic areas. Its work sits firmly on the research and development side of healthcare, where the real test is whether better computational tools can help create a stronger pipeline of potential medicines.
The company’s 2026 activity includes a collaboration with Johnson & Johnson and a continued push to build its drug-design engine into a clinical candidate pipeline. That makes Isomorphic Labs an important company to follow for anyone watching how advanced biology and drug discovery are converging.
4. Chai Discovery
Chai Discovery builds models for molecular and antibody design, giving pharmaceutical researchers new ways to evaluate and generate potential drug candidates. It has become one of the more visible names in the field because it connects model development with real pharmaceutical research use cases.
In an August LinkedIn update, Chai Discovery said Pfizer would deploy its models and named Novartis as a user of its generative-design suite. Those are company statements, but they signal why Chai is attracting attention: the company is trying to turn technical capability into practical research adoption at large pharmaceutical organizations.
5. Perceptic
Perceptic emerged from stealth with a focused proposition for pharmaceutical R&D: a scientific-intelligence layer designed to support asset scouting, scientific evaluation, and clinical-data work.
The company is early, but that is part of the appeal. Perceptic represents a shift toward healthcare software that helps research teams bring scattered scientific and clinical information into a more useful decision-making workflow. Accel says the platform is already used by pharmaceutical companies, biotechs, and CROs. That is an investor-reported claim, not an independent performance measure, but it is a useful signal of where the company is gaining traction.
6. InduPro
InduPro is developing therapies for cancer and autoimmune disease, led by a bispecific antibody-drug conjugate program called IDP-001. Its approach is built around bringing molecules into close proximity to trigger desired biological effects.
The company recently moved IDP-001 into Phase 1 testing. That clinical transition is the story to watch. It turns an interesting scientific platform into a real test of whether the approach can translate into a therapy for patients. InduPro has also maintained a visible LinkedIn presence around the program’s development.
7. Epicrispr Biotechnologies
Epicrispr Biotechnologies is working on programmable epigenetic medicines. Its lead program, EPI-321, targets facioscapulohumeral muscular dystrophy, also known as FSHD, a rare muscle disease.
The company is advancing EPI-321 toward pivotal studies. Epigenetic medicine remains a demanding scientific area, but Epicrispr Biotechnologies has a clear patient-focused objective and a development path that makes it one of the more interesting rare-disease companies to follow this year.
8. Ratio Therapeutics
Ratio Therapeutics develops targeted radiopharmaceuticals, a fast-moving area of oncology that pairs cancer-targeting molecules with radioactive payloads. Its lead clinical candidate, RTX-2358, is being studied for advanced sarcomas.
Ratio Therapeutics is pushing forward on both clinical development and the manufacturing infrastructure needed to make targeted radiopharmaceuticals more practical at scale. That combination makes the company relevant beyond its own pipeline, because manufacturing will be one of the defining challenges for the radiopharmaceutical field.
9. Vaderis Therapeutics
Vaderis Therapeutics is developing targeted medicines for rare vascular diseases. Its lead candidate, engasertib, is an oral treatment in development for hereditary hemorrhagic telangiectasia, or HHT.
The global Phase 3 HEROIC study is the company’s central milestone. HHT has limited treatment options, and a late-stage study gives Vaderis Therapeutics the opportunity to show whether engasertib can deliver a meaningful new option for patients and clinicians in a neglected disease area.
10. Antiverse
Antiverse uses computational and laboratory approaches to design antibodies against difficult drug targets. It is pursuing a class of discovery problems that have often been expensive, slow, or technically challenging for traditional approaches.
Its research agreement with the Cystic Fibrosis Foundation gives Antiverse a clear disease-focused story. The partnership is more meaningful than a generic platform announcement because it connects the company’s technology to a specific area of unmet clinical need.
What this list says about healthcare innovation in 2026
The strongest healthcare companies are being judged by what they can move forward: more consistent preventative care, stronger population-health programs, more capable research teams, earlier detection, and therapies that address difficult diseases.
For readers tracking the sector, the useful question is which startups are creating a meaningful next step for patients, providers, and healthcare systems. In 2026, these ten companies offer ten different answers.
